Evidence map›Paper›PMID 42847125›Full record

ArticleEndocrine oncology (Bristol, England)2026

Reproductive Function in Thyroid Cancer Survivors: A Gender-Based Perspective on Outcomes.

Rossella Mazzilli, Francesco Felicetti, Virginia Zamponi, Alice Nervo, Elisa Vaccaro, Giuseppe Defeudis, Emanuela Arvat, Antongiulio Faggiano

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine oncology (Bristol, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rossella MazzilliEndocrinology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome , Rome, Italy.ORCID 0000-0001-6707-3413
Francesco FelicettiDivision of Oncological Endocrinology, Città della Salute e della Scienza Hospital, Turin, Italy; Department of Medical Sciences, University of Turin , Torino, Italy.
Virginia ZamponiEndocrinology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome , Rome, Italy.
Alice NervoDivision of Oncological Endocrinology, Città della Salute e della Scienza Hospital, Turin, Italy; Department of Medical Sciences, University of Turin , Torino, Italy.
Elisa VaccaroDivision of Oncological Endocrinology, Città della Salute e della Scienza Hospital, Turin, Italy; Department of Medical Sciences, University of Turin , Torino, Italy.
Giuseppe DefeudisDepartment of Theoretical and Applied Sciences, eCampus University , Novedrate CO, Italy.
Emanuela ArvatDivision of Oncological Endocrinology, Città della Salute e della Scienza Hospital, Turin, Italy; Department of Medical Sciences, University of Turin , Torino, Italy.
Antongiulio FaggianoEndocrinology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome , Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThyroid cancer is one of the most common endocrine malignancies, with an excellent long-term survival rate. As survivorship increases, attention has shifted toward chronic endocrine sequelae, including disturbances of gonadal function and fertility. Thyroid cancer therapies, including thyroidectomy, long-term thyroid-stimulating hormone (TSH) suppressive therapy, radioiodine (RAI), and targeted systemic treatments, may interfere with reproductive health through complex endocrine and gonadal mechanisms.

objectiveThis narrative review aims to examine the pathophysiological pathways linking thyroid cancer and its treatments to reproductive health in both men and women.

resultsThyroidectomy and chronic TSH suppression may alter sex steroid bioavailability and gonadotropin regulation through changes in thyroid hormone signalling and sex hormone binding globulin synthesis. RAI therapy exerts dose-dependent gonadotoxic effects, particularly affecting ovarian reserve and spermatogenesis, often in a transient and reversible manner, but potentially accelerating reproductive aging and damage. Targeted therapies may also contribute to reproductive dysfunction, through indirect systemic and endocrine mechanisms; however, data on thyroid cancer patients are still limited.

conclusionsThyroid cancer related reproductive dysfunction may arise from the interaction of endocrine, and treatment related mechanisms. Although often subclinical, these alterations are biologically relevant and may influence long-term fertility potential. An accurate counselling for fertility management in thyroid cancer survivors appears relevant and highlights areas for future research.

Indexed as

differentiated thyroid cancerFertilityHypogonadismOvarian reserveRadioiodine therapySpermatogenesisThyroid cancer survivorsTSH suppression

Identifiers

PMID42847125
PMCPMC13695393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.